Form 8-K

8-K — Replimune Group, Inc.

Accession: 0001104659-26-092246

Filed: 2026-08-07

Period: 2026-08-06

CIK: 0001737953

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2622487d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622487d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2622487d1_ex99-2.htm)

GRAPHIC (tm2622487d1_ex99-2img001.jpg)

GRAPHIC (tm2622487d1_ex99-2img002.jpg)

GRAPHIC (tm2622487d1_ex99-2img003.jpg)

GRAPHIC (tm2622487d1_ex99-2img004.jpg)

GRAPHIC (tm2622487d1_ex99-2img005.jpg)

GRAPHIC (tm2622487d1_ex99-2img006.jpg)

GRAPHIC (tm2622487d1_ex99-2img007.jpg)

GRAPHIC (tm2622487d1_ex99-2img008.jpg)

GRAPHIC (tm2622487d1_ex99-2img009.jpg)

GRAPHIC (tm2622487d1_ex99-2img010.jpg)

GRAPHIC (tm2622487d1_ex99-2img011.jpg)

GRAPHIC (tm2622487d1_ex99-2img012.jpg)

GRAPHIC (tm2622487d1_ex99-2img013.jpg)

GRAPHIC (tm2622487d1_ex99-2img014.jpg)

GRAPHIC (tm2622487d1_ex99-2img015.jpg)

GRAPHIC (tm2622487d1_ex99-2img016.jpg)

GRAPHIC (tm2622487d1_ex99-2img017.jpg)

GRAPHIC (tm2622487d1_ex99-2img018.jpg)

GRAPHIC (tm2622487d1_ex99-2img019.jpg)

GRAPHIC (tm2622487d1_ex99-2img020.jpg)

GRAPHIC (tm2622487d1_ex99-2img021.jpg)

GRAPHIC (tm2622487d1_ex99-2img022.jpg)

GRAPHIC (tm2622487d1_ex99-2img023.jpg)

GRAPHIC (tm2622487d1_ex99-2img024.jpg)

GRAPHIC (tm2622487d1_ex99-2img025.jpg)

GRAPHIC (tm2622487d1_ex99-2img026.jpg)

GRAPHIC (tm2622487d1_ex99-2img027.jpg)

GRAPHIC (tm2622487d1_ex99-2img028.jpg)

GRAPHIC (tm2622487d1_ex99-2img029.jpg)

GRAPHIC (tm2622487d1_ex99-2img030.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622487d1_8k.htm · Sequence: 1

false

0001737953

2026-08-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): August 6, 2026

REPLIMUNE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38596

82-2082553

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

500

Unicorn Park Drive

Suite 303

Woburn, MA 01801

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including

area code: (781) 222-9600

Check the appropriate box below if the Form 8-K filing is

intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

REPL

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this

chapter). Emerging growth company ¨

If an

emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On August 6, 2026, Replimune Group, Inc.

(the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted accelerated approval

for TUDRIQEVTM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment

of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen. Continued

approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). A copy

of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. In

addition, the Company posted to its website a corporate presentation in connection with the approval. A copy of the corporate presentation

is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.

Description

99.1

News Release dated August 6, 2026

99.2

Company Presentation dated August 6, 2026

104

Cover page interactive data file (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly

authorized.

REPLIMUNE GROUP, INC.

Date: August 6, 2026

By:

/s/ Sushil Patel

Sushil Patel

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622487d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Replimune

Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous

Melanoma After Progression on an anti-PD-1 Based Regimen

Broad label to address

high unmet need in advanced melanoma

Replimune will host conference

call on August 6, 2026 at 4:30 p.m. ET.

WOBURN, Mass., August 6, 2026 (GLOBE

NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel

oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for TUDRIQEVTM

(vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable

advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen.This indication is approved under

accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent

on verification of clinical benefit in a confirmatory trial(s).

The IGNYTE trial enrolled 140 patients

with 91 patients with at least one non-injected lesion included in the efficacy-evaluable population. In this population, TUDRIQEV plus

nivolumab achieved an objective response rate (ORR) of 24.2%, with a median duration of response of 14.1 months. Treatment was well tolerated

with mostly mild-to-moderate adverse events. The patient population included patients with Stage 4 disease (80%), prior anti-PD-1 adjuvant

treatment (13%), PD-L1 negative status (54%), lung (45%) and liver lesions (24%). The IGNYTE study data were published in the Journal

of Clinical Oncology and are available here.

“This is a transformative moment for Replimune, marking years

of pioneering research to bring TUDRIQEV to patients desperately in need of new treatment options for advanced melanoma,” said

Sushil Patel, Ph.D., CEO of Replimune. “We are deeply grateful to the melanoma community, including patients and investigators

who participated in the clinical trial, for their tremendous support of this approval. We also would like to thank the FDA for recognizing

the urgency to get this therapy to patients. Replimune is now focused on critical activities to deliver TUDRIQEV to as many patients

as possible.”

There are limited treatment options for advanced melanoma, and more

than half of patients experience progression within six months of treatment on immune checkpoint inhibitors like anti-PD-1 therapy. These

patients face a poor prognosis, with a median overall survival of less than one year following progression.

“Advanced melanoma patients have few options after anti-PD-1

therapy and face high morbidity and poor survival outcomes,” said Michael K. Wong, MD, PhD, primary investigator of the IGNYTE

study and Former Physician in Chief and Professor of Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY. “With

the approval of TUDRIQEV, we have a potent oncolytic immunotherapy that can be used in a broad population, including BRAF-naïve

or pretreated, and adjuvant relapsed patients. Importantly, the therapy in combination with nivolumab drives immune activation with a

favorable risk-benefit profile and can be injected into superficial and visceral lesions.”

“The approval of RP1 in combination with nivolumab is a meaningful

step forward for patients with advanced melanoma who have failed to benefit from immunotherapy,” said Sam Guild, President of AIM

at Melanoma. “Every year, more than 8,500 people die of melanoma in the U.S., and new treatment options are urgently needed.”

TUDRIQEV combined with nivolumab was well-tolerated. The most common

(incidence ≥ 10%) adverse reactions in patients treated with TUDRIQEV combined with nivolumab were nausea, diarrhea, vomiting, constipation,

decreased appetite, abdominal pain, fatigue, pyrexia, chills, injection site reaction, influenza like illness, infections, musculoskeletal

pain, arthralgia, headache, dizziness, cough, dyspnea, rash, pruritic and hemorrhage.1 Most treatment-related adverse reactions

were grade 1 and 2 and transient.1 There were no grade 4 or 5 common adverse events. See additional Important Safety Information

below.

TUDRIQEV is administered via direct intratumor injection into superficial

and deep and/or visceral lesions1. For deep/visceral tumors, administration is guided by imaging technology.1 The

recommended dose of TUDRIQEV is based on tumor size.1

To verify the clinical benefit of TUDRIQEV, a confirmatory Phase 3

trial, IGNYTE-3, is ongoing and assessing TUDRIQEV in combination with nivolumab (NCT06264180). For additional information about

the trial, please visit https://replimune.com/clinical-trials/ignyte-3/.

Replimune is committed to helping patients in the U.S. with advanced

melanoma gain access to treatment with TUDRIQEV. Eligible patients who are prescribed TUDRIQEV will have access to ReplimuneConnect Plus,

a comprehensive program offering information on access, reimbursement and financial support.

Webcast Details

Replimune will host a webcast featuring members from the management

team to discuss today’s developments at 4:30 p.m. ET on Thursday, August 6, 2026.

Listeners can register for the webcast

via this link. Analysts wishing to participate in the question and answer session should use this link. A replay

of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion.

Those who plan on participating are advised to join 15 minutes prior to the start time.

About Melanoma

Melanoma is the fifth most common cancer, with approximately 105,000

new cases estimated in the U.S. in 2025, and the most lethal form of skin cancer, accounting for nearly 8,500 deaths annually. Standard

of care therapy includes treatment with immune checkpoint blockade, to which approximately half of patients will not respond or will

progress after treatment. Melanoma is considered advanced when the cancer spreads beyond the primary tumor to other parts of the body.

About IGNYTE

IGNYTE (NCT03767348) is an open-label, multicenter Phase 1/2 study

evaluating the safety and efficacy of vusolimogene oderparepvec as monotherapy or in combination with nivolumab in adult patients with

advanced solid tumors, including a registrational cohort of patients with advanced melanoma with confirmed progression on an anti-PD-1

containing regimen treated with vusolimogene oderparepvec plus nivolumab.

The anti-PD-1 failed melanoma registrational

cohort included 140 patients who received vusolimogene oderparepvec plus nivolumab after confirmed progression while being treated for

at least eight weeks with anti-PD-1 based therapy, with or without anti-CTLA-4. Of the 140 patients, 91 patients with at least one noninjected

lesion were included in the efficacy-evaluable population.

About TUDRIQEVTM

(vusolimogene oderparepvec-wtpg)

TUDRIQEV (vusolimogene oderparepvec-wtpg) is a genetically modified

herpes simplex virus, type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus

with the R sequence deleted (GALV-GP-R–) and human granulocyte macrophage colony-stimulating factor (GM-CSF). The genes encoding

the HSV-1 neurovirulence factor ICP34.5 and the transporter associated with antigen presentation inhibitor ICP47 are deleted from TUDRIQEV.

TUDRIQEV preferentially replicates within the tumor leading to tumor lysis, release of tumor and viral antigens, proinflammatory molecules,

and infiltration of T cells. The GALV-GP-R– expressed by TUDRIQEV increases direct tumor killing and the GM-CSF expressed by TUDRIQEV

is intended to activate and mature dendritic cells and monocytes. In the anti-PD-1 resistant setting, TUDRIQEV and nivolumab in combination

may promote anti-tumor immune response. To learn more, visit tudriqev.com.

INDICATION

TUDRIQEV (vusolimogene oderparepvec-wtpg) is indicated in combination

with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression

with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective

response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit

in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions Accidental

Exposure to TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact

with injected tumors, dressings, or bodily fluids of patients. Should accidental exposure occur, clean the affected area. Herpetic Infection

or Reactivation: Assess and treat suspected herpetic lesions as clinically warranted. Visceral Injury: Monitor patients for signs and

symptoms of visceral injury during and after TUDRIQEV administration and manage accordingly.

Adverse Reactions

Serious adverse reactions occurred in 35% of 140 patients who received

TUDRIQEV in combination with nivolumab including 2 patients each with arthralgia, hypophysitis, immune-mediated enterocolitis, and pyrexia.

Adverse reactions leading to permanent TUDRIQEV discontinuation occurred in 2.9% of 140 patients and were 1 each of amylase increased,

lipase increased, myocarditis, and pneumonitis.

Most common non-laboratory adverse reactions (incidence ˃ 10%)

are fatigue, pyrexia, chills, musculoskeletal pain, nausea, diarrhea/colitis, injection site reaction, headache, cough, influenza like

illness, vomiting, pruritus, arthralgia, asthenia, constipation, decreased appetite, dizziness, skin/superficial infection, and dyspnea.

Drug interactions:

Antivirals: delay TUDRIQEV administration for 72 hours.

Special Populations

Females and Males of Reproductive Potential: Advise females of reproductive

potential, and males with a female partner of reproductive potential to use effective contraception during TUDRIQEV treatment and for

90 days after the last dose.

Please report any adverse event or

product quality complaint related to a Replimune product by calling 1-877-375-0095. If you prefer, you may contact

the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here

for full Prescribing Information, including Patient Information.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded

in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies, including the

Company’s first commercially available product TUDRIQEVTM (vusolimogene oderparepvec-wtpg), approved under accelerated

approval by the U.S. Food and Drug Administration in combination with nivolumab for the treatment of adults with advanced melanoma who

experienced disease progression on a PD-1 antibody-based regimen. Replimune’s proprietary RPx platform is based on a potent HSV-1

backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. Upon intratumor injection, RPx

causes direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens, alteration of the tumor

microenvironment, and when dosed in combination with an immune checkpoint inhibitor immunotherapy, it may ignite a systemic anti-tumor

response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities,

leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information on Replimune,

please visit www.replimune.com and follow us on social media at LinkedIn and X.

Forward Looking Statements

This press release contains forward looking statements within the

meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated

patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), regulatory

applications and related submission contents and timelines, the timelines or outcomes related to litigation, including any rehearings

or appeals of decisions in any such proceedings, and our ability to execute on our strategic or financial initiatives, our estimates

regarding future expenses, capital requirements and needs for additional financing, and potential commercial viability, and potential

reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from

those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of

TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements may be identified

by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,”

“should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking

statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which

are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements.

These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify

the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing

goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials,

changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates,

the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our

Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission.

Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking

statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking

statements.

Investor Inquiries

Chris Brinzey

ICR Westwicke

339.970.2843

chris.brinzey@westwicke.com

Media Inquiries

Arleen Goldenberg

Replimune, Inc.

917.548.1582

media@replimune.com

[i] TUDRIQEV Prescribing Information. Last updated: 08/26.

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2622487d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

© 2026 Replimune Group Inc. TUDRIQEV TM Approval Call © 2026 Replimune Inc. 2 Safe Harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), regulatory applications and related submission contents and timelines, the timelines or outcomes related to litigation, including any rehearings or appeals of decisions in any such proceedings, and our ability to execute on our strategic or financial initiatives, our estimates regarding future expenses, capital requirements and needs for additional financing, and potential commercial viability, and potential reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward - looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward - looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE - 3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10 - K and Quarterly Reports on Form 10 - Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward - looking statements. Forward - looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward - looking statements.

© 2026 Replimune Group Inc. TUDRIQEV TM Approval Call © 2026 Replimune Inc. 3 Agenda Introduction • Sushil Patel, PhD, CEO TUDRIQEV TM U.S. Prescribing Information • Kostas Xynos, MD, PhD, MBA, Chief Medical Officer U.S. Launch Plans • Sushil Patel, PhD, CEO Value and Milestones • Emily Hill, CFO Q&A Session

5 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 5 FDA Approval Validates RPx Platform First Oncolytic Viral Combination Therapy to Drive Immune Activation TUDRIQEV is Replimune’s First A pproved Product V alidating the RPx Platform TUDRIQEV Delivers Hope for Advanced M elanoma P atients

6 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 6 TUDRIQEV (formerly known as RP1) is Now FDA Approved Approved in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experience disease progression with a PD - 1 blocking antibody - based regimen “Too - drih - kev” This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.

7 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 7 TUDRIQEV Label Reflects Broad Patient Population Demonstrated effect in non - injected lesions in combination with nivolumab No requirement for prior BRAF treatment Ability to treat superficial, deep and visceral lesions, including lung, liver and other organs Patients can be retreated based on physician discretion

9 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 9 IGNYTE Study: Basis of Accelerated Approval of TUDRIQEV References: 1. TUDRIQEV. Prescribing Information. Replimune, Inc.; 2025. TUDRIQEV Cycle 1 1x10 6 PFU/mL (up to 10 mL) TUDRIQEV 1x10 7 PFU/mL (up to 10 mL) + Nivolumab Cycles 2 - 8 Cycles 9 - 30+ Nivolumab TUDRIQEV 1x10 7 PFU/mL (up to 10 mL) Additional cycles* * Retreatment : At investigator discretion, patients may be retreated with TUDRIQEV at a concentration of 10 7 PFU/mL every 2 weeks. In IGNYTE, patients were retreated with TUDRIQEV + nivolumab or as a monotherapy if nivolumab was previously stopped due to toxi cit y related to nivolumab. Every 2 weeks Every 2 weeks Major efficacy outcome measures • Safety & tolerability • ORR • DOR Confirmed progression while on prior anti - PD - 1 therapy

10 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 10 Patient Demographics Reflect Real World Hard - to - Treat Population N=91* Demographics and Disease Characteristics 62 (23, 91) Age, median, years (range) 80% Stage IV disease 13% Prior anti - PD1 adjuvant 54% Tumor PD - L1 expression negative 45% Lung lesions 24% Liver lesions 7% Brain lesions No overall difference in safety or effectiveness in patients over 65 years of age (41%), including patients over 75 years old (14%) *140 patients were enrolled in IGNYTE, 91 patients with at least 1 non - injected lesion were included in the efficacy - evaluable population

11 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 11 TUDRIQEV Prescribing Information Efficacy Summary a Assessed by blinded central IRC per RECIST 1.1 criteria, b The median duration of follow - up for DoR was 29.5 (95% CI: 18.4 - 33.1) months by Kaplan - Meier method, c Estimated by Kaplan - Meier method, d Observed duration of response, IRC, independent review committee; NR, not reached N=91* Objective Response Rate by IRC 24.2 (15.8, 34.3) ORR% (95% CI) a N=91 Duration of Response (DoR) b 14.1 (10.7, NR) Median DoR in months (95% CI) c 3.9 to 34.6+ DoR range, months 86.1 Patients with DoR > 6 months, n (%) d 54.6 Patients with DoR > 12 months, n (%) d *140 patients were enrolled in IGNYTE, 91 patients with at least 1 non - injected lesion were included in the efficacy - evaluable population

12 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 12 Simple and Practical Dosing and Administration Highlights from Label • Simple dosing calculation for healthcare providers – 1mL/cm per tumor up to a max of 10mL per dose • Tumor selection flexibility – prioritize the most rapidly growing and largest new or existing lesions suitable for injection • Scheduling flexibility – TUDRIQEV + nivolumab do not have to be scheduled on the same day • Patients can receive additional doses at the physician’s discretion • Ability to inject superficial AND visceral lesions

13 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 13 TUDRIQEV Administration to Superficial Tumors Injection Administration for Nonulcerated Superficial Tumors Injection Administration for Ulcerated Cutaneous Tumors

14 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 14 TUDRIQEV Injection for Deep or Visceral Tumors including Lung, Kidney or other Organs Radial Injection Administration for Deep or Visceral Tumor Coaxial Injection Administration in Visceral Tumor with Image Guidance

15 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 15 Key TUDRIQEV Safety Highlights No Contraindications Warnings & Precautions • Accidental exposure to TUDRIQEV, herpetic infection or reactivation, injection procedure complications, immune - mediated events Most common ( > 10%) adverse reactions • Nausea, diarrhea, vomiting, constipation, decreased appetite, abdominal pain, fatigue, pyrexia, chills, injection site reaction, influenza like illness, edema, infections, musculoskeletal pain, arthralgia, headache, dizziness, cough, dyspnea, rash, pruritis , hemorrhage • No grade 4 or 5 common adverse events observed Drug interactions • Antiviral medications may reduce the efficacy of TUDRIQEV. No reported transmission TUDRIQEV to close contacts Recommended Biosafety Level 1 (lowest level) Standard cleaning procedures

16 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 16 Confirmatory IGNYTE - 3 Study: Enrollment On Track *Nivolumab - Relatlimab ( Opdualag ), Chemotherapy (DTIC, TMZ, paclitaxel/nab - paclitaxel), Rechallenge with anti - PD1 monotherapy (nivo or pembro ); NCT6264180 Randomized 1:1 RP1 + Nivolumab (n=200) Treatment of Physician’s Choice (TPC*) (n=200) Advanced cutaneous melanoma Progressed on anti - PD1 AND anti - CTLA - 4 OR not candidates for anti - CTLA - 4 N=~400 Primary Analysis – OS Secondary Endpoints - PFS/ORR

18 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 18 ~10K Addressable Patients Across Lines of Therapy 3L+ 2L Early Stage 1L US Melanoma Patient Treatment Funnel ~80% of patients who progress on PD - 1 across lines of therapy are injectable (~10K addressable patients) RP1 potential patients PD - 1 Containing Regimens Surgery Only BRAF/ MEK PD - 1 Containing Regimens 1 ~2K Adj refractory ~7K No SOC * ~4K No SOC * 1De - novo metastatic or recurrent from surgery. *Therapy is dependent on prior exposure (e.g. PD - 1 regimen, BRAF+MEK, TIL, or ch emo) Source: Epi data for year 2030 from CancerMPact ® Patient Metrics, Oracle (available from www.cancermpact.com Accessed 15 Oct 2025), with adjustments to future 2L+ treatment ra tes based on primary market research. Injectability based on primary market research and real - world data analysis.

19 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 19 Positioning TUDRIQEV to be the 1st Choice after PD - 1 Progression Compelling data and favorable safety profile Ensure a positive TUDRIQEV experience while creating a seamless treatment journey Deliver a meaningful TUDRIQEV value proposition supporting access for all customers Instill confidence in TUDRIQEV to drive targeted and rapid adoption upon 1st PD - 1 progression

20 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 20 Account Profiling Enabled Identification of Physician Champions to Drive Rapid Adoption Early Adopter Accounts (n=~200) California Texas Florida 94% Medical Oncology champion identified Significant proactive requests for engagement immediately following approval 87% IR champion identified

21 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 21 Targeted Launch for Long - term Success ~450 Accounts ~1200 Accounts ~6 Month Initial Focus Longer - term Early Adopters Early Adopters + Mod - High Volume ~200 Accounts Early Adopters + High Volume Next 9 - 12 Months

22 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 22 Today’s Reimbursement Model Supports the Patient Treatment Journey Existing procedural codes to support TUDRIQEV injections by IRs and med oncs Extensive payer engagement reaching nearly 80% of covered lives anticipated to expedite formulary review and coverage decisions Reimbursement landscape supports adoption of TUDRIQEV in community and hospital settings

23 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 23 Patient Treatment Journey Aligned with Approved Product Label Patient progresses on PD - 1 and TUDRIQEV is chosen as the next therapy Nivo administered up to 2 years Oncologist and IR can collaborate to create TUDRIQEV treatment plan up to 8 cycles TUDRIQEV & Nivo treatment visits are scheduled Q2 weeks TUDRIQEV is delivered next day TUDRIQEV injections in outpatient setting with standard cleaning procedures

26 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 26 Pillars to Drive Long - Term Value U.S. based 63,000 square foot state - of - the - art manufacturing facility to support global commercial supply TUDRIQEV expected to ship in approximately 60 days Delivering value and achieving broad coverage Cost of treatment in line with comparable treatments in advanced melanoma

27 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 27 The Future of the RPx Platform Registration - Directed Clinical trials & indication Engineered HSV backbone + GM - CSF + GALV - GP R - IND/CTA Phase 1/2 2L HCC/1L BTC Maintenance + bevacizumab/atezolizumab / + durvalumab HCC/BTC REVEAL + nivolumab Metastatic Uveal Melanoma Phase 2 IGNYTE - 3 + nivolumab Melanoma (anti - PD1 failed) Approved Engineered HSV backbone + GM - CSF + GALV - GP R - + anti - CTLA - 4 IGNYTE * + nivolumab Melanoma (anti - PD1 failed) PDUFA date July 22, 2025 RPx expansion into additional solid tumors planned RP1 RP2 Randomized Controlled Trial Randomized Controlled Trial

28 TUDRIQEV TM Approval Call © 2026 Replimune Inc. 28 Anticipated Milestones in the Next 6 Months TUDRIQEV First Revenue Reporting RP2 Uveal Melanoma Ph 2/3 Study Transition Preliminary RP2 HCC/BTC Data Pipeline Expansion into Additional Solid Tumors

GRAPHIC

Filename: tm2622487d1_ex99-2img001.jpg · Sequence: 7

Binary file (106037 bytes)

Download tm2622487d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img002.jpg · Sequence: 8

Binary file (321870 bytes)

Download tm2622487d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img003.jpg · Sequence: 9

Binary file (106627 bytes)

Download tm2622487d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img004.jpg · Sequence: 10

Binary file (98194 bytes)

Download tm2622487d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img005.jpg · Sequence: 11

Binary file (111778 bytes)

Download tm2622487d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img006.jpg · Sequence: 12

Binary file (185227 bytes)

Download tm2622487d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img007.jpg · Sequence: 13

Binary file (144670 bytes)

Download tm2622487d1_ex99-2img007.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img008.jpg · Sequence: 14

Binary file (103640 bytes)

Download tm2622487d1_ex99-2img008.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img009.jpg · Sequence: 15

Binary file (186428 bytes)

Download tm2622487d1_ex99-2img009.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img010.jpg · Sequence: 16

Binary file (162958 bytes)

Download tm2622487d1_ex99-2img010.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img011.jpg · Sequence: 17

Binary file (143800 bytes)

Download tm2622487d1_ex99-2img011.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img012.jpg · Sequence: 18

Binary file (140084 bytes)

Download tm2622487d1_ex99-2img012.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img013.jpg · Sequence: 19

Binary file (159421 bytes)

Download tm2622487d1_ex99-2img013.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img014.jpg · Sequence: 20

Binary file (126261 bytes)

Download tm2622487d1_ex99-2img014.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img015.jpg · Sequence: 21

Binary file (178689 bytes)

Download tm2622487d1_ex99-2img015.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img016.jpg · Sequence: 22

Binary file (124228 bytes)

Download tm2622487d1_ex99-2img016.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img017.jpg · Sequence: 23

Binary file (80524 bytes)

Download tm2622487d1_ex99-2img017.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img018.jpg · Sequence: 24

Binary file (139857 bytes)

Download tm2622487d1_ex99-2img018.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img019.jpg · Sequence: 25

Binary file (115442 bytes)

Download tm2622487d1_ex99-2img019.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img020.jpg · Sequence: 26

Binary file (194474 bytes)

Download tm2622487d1_ex99-2img020.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img021.jpg · Sequence: 27

Binary file (89077 bytes)

Download tm2622487d1_ex99-2img021.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img022.jpg · Sequence: 28

Binary file (138363 bytes)

Download tm2622487d1_ex99-2img022.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img023.jpg · Sequence: 29

Binary file (123895 bytes)

Download tm2622487d1_ex99-2img023.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img024.jpg · Sequence: 30

Binary file (196361 bytes)

Download tm2622487d1_ex99-2img024.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img025.jpg · Sequence: 31

Binary file (79935 bytes)

Download tm2622487d1_ex99-2img025.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img026.jpg · Sequence: 32

Binary file (137909 bytes)

Download tm2622487d1_ex99-2img026.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img027.jpg · Sequence: 33

Binary file (132683 bytes)

Download tm2622487d1_ex99-2img027.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img028.jpg · Sequence: 34

Binary file (102852 bytes)

Download tm2622487d1_ex99-2img028.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img029.jpg · Sequence: 35

Binary file (62656 bytes)

Download tm2622487d1_ex99-2img029.jpg

GRAPHIC

Filename: tm2622487d1_ex99-2img030.jpg · Sequence: 36

Binary file (70183 bytes)

Download tm2622487d1_ex99-2img030.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 38

v3.26.1

Cover

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity File Number

001-38596

Entity Registrant Name

REPLIMUNE GROUP, INC.

Entity Central Index Key

0001737953

Entity Tax Identification Number

82-2082553

Entity Incorporation, State or Country Code

Entity Address, Address Line One

500

Unicorn Park Drive

Entity Address, Address Line Two

Suite 303

Entity Address, City or Town

Woburn

Entity Address, State or Province

Entity Address, Postal Zip Code

01801

City Area Code

781

Local Phone Number

222-9600

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

REPL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration